LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia Ilker Tasci, Gokhan Erdem, Gokhan Ozgur, Serkan Tapan, Teoman Dogru, Halil Genc, Cengizhan Acikel, Taner Ozgurtas, Alper Sonmez Atherosclerosis Volume 204, Issue 1, Pages 222-228 (May 2009) DOI: 10.1016/j.atherosclerosis.2008.08.030 Copyright © 2008 Elsevier Ireland Ltd Terms and Conditions
Fig. 1 Study design and follow-up of patients through the trial. C: cholesterol. Atherosclerosis 2009 204, 222-228DOI: (10.1016/j.atherosclerosis.2008.08.030) Copyright © 2008 Elsevier Ireland Ltd Terms and Conditions
Fig. 2 Plasma concentration of apelin at baseline, 12-week and 24-week time points. Changes in plasma apelin level in responders to TLC (a), and in non-responders by the 12th week who received rosuvastatin treatment and achieved LDL-cholesterol goal by the 24th week (b). *p<0.05. Exact values for apelin are given in Tables 3 and 4. Atherosclerosis 2009 204, 222-228DOI: (10.1016/j.atherosclerosis.2008.08.030) Copyright © 2008 Elsevier Ireland Ltd Terms and Conditions